This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn

This study has been completed.
Information provided by:
Novartis Identifier:
First received: June 17, 2008
Last updated: January 13, 2010
Last verified: January 2010
Heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach. This study will investigate the safety and efficacy of lansoprazole 15 mg or 30 mg administered once a day in preventing frequent nighttime heartburn.

Condition Intervention Phase
Frequent Heartburn Drug: Lansoprazole Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of Fourteen Day Treatment With Lansoprazole 15 mg or 30 mg Once a Day in Frequent Nighttime Heartburn

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percentage of nighttimes with no heartburn during 14 days of double-blind treatment in subjects with frequent heartburn. [ Time Frame: 14 days ]

Secondary Outcome Measures:
  • Proportion of 24 hour days with no heartburn during 14 days of treatment. Proportion of subjects with no heartburn during day 1 (the 24 hours following the first dose. The evaluation of lansoprazole safety. [ Time Frame: 14 days ]

Enrollment: 852
Study Start Date: January 2007
Study Completion Date: August 2007
Arms Assigned Interventions
Experimental: 1
15 mg lansoprazole
Drug: Lansoprazole
Lansoprazole 15 mg once per day for 14 days
Other Name: Prevacid - United States
Experimental: 2
30 mg lansoprazole
Drug: Lansoprazole
Lansoprazole 30 mg once per day for 14 days
Placebo Comparator: 3
Drug: placebo


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Experiencing heartburn at least 2 days per week during the nighttime period over the past month.
  • Having heartburn that responds to heartburn medication.
  • Be willing to discontinue the use of heartburn treatment for 7 days prior to inclusion in the study.

Exclusion Criteria:

  • Having history of erosive esophagitis or gastroesophageal reflux disease diagnosed by a physician and confirmed by testing (endoscopy).
  • Be unwilling to take only the study medication, and antacid provided as a rescue medication for relief of acute heartburn during the study.

"Other protocol-defined inclusion/exclusion criteria may apply"

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00701259

United States, New Jersey
Not applicable - enrollment complete
Parsippany, New Jersey, United States, 07054
Sponsors and Collaborators
  More Information

Responsible Party: Regulatory Affairs, Novartis Identifier: NCT00701259     History of Changes
Other Study ID Numbers: PRSW-GN-305
Study First Received: June 17, 2008
Last Updated: January 13, 2010

Keywords provided by Novartis:
Frequent heartburn, proton pump inhibitor, lansoprazole
Treatment of
over 14 days

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on June 22, 2017